je.st
news
Home
› Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
2015-04-01 08:23:10| drugdiscoveryonline Home Page
Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer
Tags: trial
phase
approval
cancer
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||